The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Stock and Other Ownership Interests - Bavarian Nordic
Travel, Accommodations, Expenses - Repare Therapeutics
(OPTIONAL) Uncompensated Relationships - Amgen (Inst); Eikon Therapeutics (Inst); Incyte (Inst); Kinnate Biopharma (Inst); Repare Therapeutics; SERVIER (Inst)
Integrating deep proteomics into precision oncology for multi-omics characterization of metastatic cancer.
 
Juanjuan Wang
No Relationships to Disclose
 
Annelaura Bach Nielsen
No Relationships to Disclose
 
Filip Mundt
No Relationships to Disclose
 
Luca Robinson
No Relationships to Disclose
 
Martina Eriksen
Consulting or Advisory Role - Pierre Fabre
Travel, Accommodations, Expenses - Pierre Fabre
 
Christina Yde
No Relationships to Disclose
 
Camilla Qvortrup
Consulting or Advisory Role - Merck KGaA; Pierre Fabre
Research Funding - miratis (Inst); MSD Oncology (Inst); Pfizer (Inst); pierre fabre (Inst); Roche (Inst); SERVIER (Inst)
Travel, Accommodations, Expenses - Merck KGaA (Inst); Pierre Fabre (Inst); Roche (Inst); SERVIER (Inst)
 
Ulrik Lassen
Honoraria - Bayer; Novartis; Pfizer
Consulting or Advisory Role - Bayer; Pfizer
Research Funding - BMS (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Lilly (Inst); Pfizer (Inst); Roche (Inst)
 
Anand Loya
No Relationships to Disclose
 
Iben Spanggaard
Honoraria - AstraZeneca
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); Bioinvent (Inst); BioNTech SE (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CDR-Life (Inst); Dragonfly Therapeutics (Inst); Genentech (Inst); Genmab (Inst); Incyte (Inst); Loxo/Bayer (Inst); Loxo/Lilly (Inst); MonTa Biosciences (Inst); MSD (Inst); Novartis (Inst); Orion (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Repare Therapeutics (Inst); Roche (Inst); Symphogen (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Incyte
 
Martin Højgaard
No Relationships to Disclose
 
Frederik Otzen Bagger
Stock and Other Ownership Interests - Bavarian Nordic; Fobinf ApS
Honoraria - AstraZeneca
Consulting or Advisory Role - Hervolution; Immunitrack; InProTher; Lilly
Other Relationship - Fobinf Holding ApS
 
Kristoffer Rohrberg
Honoraria - MSD; MSD
Consulting or Advisory Role - Abbvie; Genmab
Research Funding - Alligator Bioscience (Inst); AstraZeneca (Inst); Bayer (Inst); Bioinvent (Inst); BioNTech SE (Inst); Bristol-Myers Squibb (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Lilly (Inst); Loxo (Inst); Merus (Inst); MonTa Biosciences (Inst); MSD (Inst); Navire (Inst); Novartis (Inst); Orion Clinical (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Repare Therapeutics (Inst); Roche/Genentech (Inst); Symphogen (Inst); Turning Point Therapeutics (Inst)
Travel, Accommodations, Expenses - AstraZeneca (Inst)
 
Matthias Mann
Stock and Other Ownership Interests - Evosep